Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Small Cap Foreign Biotech -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (71)	2/28/2001 4:24:44 AM
From: nigel bates	Read Replies (1) \| Respond to of 363

LONDON, Feb 28 (Reuters) - British biotechnology company Pharmagene Plc (LSE: PGN.L - news) said on Wednesday it had signed a drug discovery agreement with Germany's Bayer AG in the field of respiratory disease. The UK company, whose shares have slumped since it floated last year, specialises in using human tissues in pre-clinical tests. Under the new agreement, Bayer will use Pharmagene's expertise in human tissue to build a dataset to aid the validation of potential drug targets identified by Bayer. Target validation is a key step in the discovery process but is currently a major bottleneck in pharmaceutical R&D. No financial terms of the latest Bayer deal were disclosed. Bayer has been working with Pharmagene since October 1999. Other clients include GlaxoSmithKline , Pfizer , Janssen and Merck and Co ...